A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk
Status:
Withdrawn
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the effect of treatment for hepatitis C virus (HCV) on cardiovascular
disease risk. The study will enroll men and women who are infected with HCV and have
underlying metabolic disease. All participants will receive a 12-week course of an HCV
treatment (elbasvir/grazoprevir). Cardiovascular disease risk will be evaluated at baseline,
week 4 on treatment, 12 weeks post-treatment, and 52 weeks post-treatment through noninvasive
measurements of endothelial function, insulin resistance, liver fibrosis and steatosis, and
circulating blood biomarkers.